Apixaban (B01AF02)

TENDER DESCRIPTION

The Kaufmännische Krankenkasse - KKH (hereinafter referred to as KKH) pursues the objective of concluding discount agreements in accordance with Section 130a(8) of the SGB V with all suitable pharmaceutical companies for the active ingredient specified under BT-21-Lot (ATC) and, if applicable, restricting them to certain dosage forms within the framework of a so-called “Open-House procedure”. Subject to uniform contract terms and a uniform access procedure, the conclusion or accession to a discount agreement in accordance with Section 130a(8) of the SGB V for the above-mentioned active ingredient is offered to all suitable and interested pharmaceutical companies or associations of pharmaceutical companies. For this purpose, interested pharmaceutical companies may request the participation documents and the contract at the contact address stated. A prerequisite for concluding a contract is that the interested pharmaceutical company submits the requested participation documents fully completed and signed. A contract is concluded with each pharmaceutical company that meets the participation requirements. Exclusivity is not granted. Accession or conclusion of the contract may be…

TENDER BRIEF

TENDER DOCUMENTS